From Precious Samples to Powerful Insights

How the SPEAR UltraDetect™ pTau 217 Assay Unlocks Greater Discrimination of Amyloid Positives Using 1 µL of Diluted Sample

Blood-based biomarkers like pTau 217 are transforming Alzheimer’s research—but achieving consistent, ultra-sensitive measurements has remained a challenge.

In this case study, see how Dr. Karikari used SPEAR UltraDetect™ to:

– Achieve 4.7× stronger separation of amyloid-positive vs. negative groups

– Generate robust results from 1 µL of diluted plasma

– Maintain precision after multiple freeze–thaw cycles

– Improve data reliability across diverse cohorts

These results show how SPEAR technology delivers exceptional sensitivity and reproducibility—empowering studies that make the most of precious biobank samples.

Unlock the full results by downloading the case study.